W Mark Saltzman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3431355/publications.pdf

Version: 2024-02-01

240 papers	20,348 citations	9775 73 h-index	12258 133 g-index
249 all docs	249 docs citations	249 times ranked	24206 citing authors

#	Article	IF	Citations
1	<scp>3D</scp> bioprinting of an implantable xenoâ€free vascularized human skin graft. Bioengineering and Translational Medicine, 2023, 8, .	3.9	9
2	Engineering alginate microparticles for optimized accumulation in fetal rat myelomeningocele. Journal of Pediatric Surgery, 2022, 57, 544-550.	0.8	4
3	Longâ€acting and extendedâ€release implant and nanoformulations with a synergistic antiretroviral twoâ€drug combination controls HIV â€1 infection in a humanized mouse model. Bioengineering and Translational Medicine, 2022, 7, e10237.	3.9	5
4	A digital pathology tool for quantification of color features in histologic specimens. Bioengineering and Translational Medicine, 2022, 7, e10242.	3.9	1
5	Direct targeting of amplified gene loci for proapoptotic anticancer therapy. Nature Biotechnology, 2022, 40, 325-334.	9.4	15
6	Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	17
7	Surface conjugation of antibodies improves nanoparticle uptake in bronchial epithelial cells. PLoS ONE, 2022, 17, e0266218.	1.1	4
8	ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage. Nature Communications, 2022, 13, 2196.	5.8	9
9	Intrathecal delivery and its applications in leptomeningeal disease. Advanced Drug Delivery Reviews, 2022, 186, 114338.	6.6	9
10	Intra-amniotic Injection of Poly(lactic-co-glycolic Acid) Microparticles Loaded with Growth Factor: Effect on Tissue Coverage and Cellular Apoptosis in the Rat Model of Myelomeningocele. Journal of the American College of Surgeons, 2022, 234, 1010-1019.	0.2	1
11	Polyglycerol and Poly(ethylene glycol) exhibit different effects on pharmacokinetics and antibody generation when grafted to nanoparticle surfaces. Biomaterials, 2022, 287, 121676.	5.7	14
12	Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. Journal of Controlled Release, 2022, 349, 354-366.	4.8	12
13	Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys. American Journal of Transplantation, 2021, 21, 161-173.	2.6	37
14	Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
15	Nanoparticles for delivery of agents to fetal lungs. Acta Biomaterialia, 2021, 123, 346-353.	4.1	15
16	Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension. JCI Insight, 2021, 6, .	2.3	35
17	The NIH Somatic Cell Genome Editing program. Nature, 2021, 592, 195-204.	13.7	84
18	Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nature Biomedical Engineering, 2021, 5, 1048-1058.	11.6	96

#	Article	IF	Citations
19	PEGylation of poly(amine-co-ester) polyplexes for tunable gene delivery. Biomaterials, 2021, 272, 120780.	5.7	39
20	Escaping the endosome: assessing cellular trafficking mechanisms of non-viral vehicles. Journal of Controlled Release, 2021, 335, 465-480.	4.8	55
21	Extracellular vesicles mediated exocytosis of antisense peptide nucleic acids. Molecular Therapy - Nucleic Acids, 2021, 25, 302-315.	2.3	8
22	Surface Topography of Polyethylene Glycol Shell Nanoparticles Formed from Bottlebrush Block Copolymers Controls Interactions with Proteins and Cells. ACS Nano, 2021, 15, 16118-16129.	7.3	16
23	Three Dimensional Bioprinting of a Vascularized and Perfusable Skin Graft Using Human Keratinocytes, Fibroblasts, Pericytes, and Endothelial Cells. Tissue Engineering - Part A, 2020, 26, 227-238.	1.6	160
24	Polymeric vehicles for nucleic acid delivery. Advanced Drug Delivery Reviews, 2020, 156, 119-132.	6.6	106
25	Ex vivo isolated human vessel perfusion system for the design and assessment of nanomedicines targeted to the endothelium. Bioengineering and Translational Medicine, 2020, 5, e10154.	3.9	7
26	High-throughput quantitative microscopy-based half-life measurements of intravenously injected agents. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3502-3508.	3.3	11
27	Peptide Nucleic Acids and Gene Editing: Perspectives on Structure and Repair. Molecules, 2020, 25, 735.	1.7	44
28	Cell interactions with polymers. , 2020, , 275-293.		3
29	Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo. Methods in Molecular Biology, 2020, 2105, 261-281.	0.4	10
30	Quantitating Endosomal Escape of a Library of Polymers for mRNA Delivery. Nano Letters, 2020, 20, 1117-1123.	4.5	59
31	Biodegradable bioadhesive nanoparticle incorporation of broadâ€spectrum organic sunscreen agents. Bioengineering and Translational Medicine, 2019, 4, 129-140.	3.9	25
32	Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity. Clinical Cancer Research, 2019, 25, 784-795.	3.2	32
33	Optimizing biodegradable nanoparticle size for tissue-specific delivery. Journal of Controlled Release, 2019, 314, 92-101.	4.8	43
34	Fas ligand and nitric oxide combination to control smooth muscle growth while sparing endothelium. Biomaterials, 2019, 212, 28-38.	5.7	14
35	Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV. Antiviral Research, 2019, 167, 110-116.	1.9	15
36	Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver. Journal of Controlled Release, 2019, 304, 259-267.	4.8	23

#	Article	IF	Citations
37	The Yale Center for Biomedical Innovation and Technology (CBIT). Academic Medicine, 2019, 94, 528-534.	0.8	11
38	Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials, 2019, 201, 87-98.	5.7	77
39	Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target. Molecular Cancer Therapeutics, 2019, 18, 413-420.	1.9	9
40	Alginate microparticles loaded with basic fibroblast growth factor induce tissue coverage in a rat model of myelomeningocele. Journal of Pediatric Surgery, 2019, 54, 80-85.	0.8	18
41	Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. JCI Insight, 2019, 4, .	2.3	17
42	From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E802-E811.	3.3	30
43	Debugging the genetic code: Non-viral inÂvivo delivery of therapeutic genome editing technologies. Current Opinion in Biomedical Engineering, 2018, 7, 24-32.	1.8	12
44	A â€œtop-downâ€•approach to actuate poly(amine-co-ester) terpolymers for potent and safe mRNA delivery. Biomaterials, 2018, 176, 122-130.	5.7	49
45	In utero nanoparticle delivery for site-specific genome editing. Nature Communications, 2018, 9, 2481.	5.8	124
46	Peptide Nucleic Acids as a Tool for Site-Specific Gene Editing. Molecules, 2018, 23, 632.	1.7	57
47	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.4	47
48	Tunability of Biodegradable Poly(amine-co-ester) Polymers for Customized Nucleic Acid Delivery and Other Biomedical Applications. Biomacromolecules, 2018, 19, 3861-3873.	2.6	43
49	Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8114-E8115.	3.3	0
50	Focus on Fundamentals: Achieving Effective Nanoparticle Targeting. Trends in Molecular Medicine, 2018, 24, 598-606.	3.5	77
51	Biodegradable PEG-poly(Ï‰-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials, 2018, 178, 193-203.	5.7	43
52	Quantitative microscopy-based measurements of circulating nanoparticle concentration using microliter blood volumes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1863-1867.	1.7	6
53	Surface chemistry governs cellular tropism of nanoparticles in the brain. Nature Communications, 2017, 8, 15322.	5.8	77
54	Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas. Molecular Cancer Therapeutics, 2017, 16, 1456-1469.	1.9	26

#	Article	IF	Citations
55	Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics, 2017, 16, 323-333.	1.9	34
56	Nanomaterials for convection-enhanced delivery of agents to treat brain tumors. Current Opinion in Biomedical Engineering, 2017, 4, 1-12.	1.8	25
57	Improved threshold selection for the determination of volume of distribution of nanoparticles administered by convection-enhanced delivery. Computerized Medical Imaging and Graphics, 2017, 62, 34-40.	3.5	5
58	Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. Nature Communications, 2017, 8, 191.	5.8	76
59	Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir. Biomaterials, 2017, 144, 144-154.	5.7	59
60	Nanoparticle targeting to the endothelium during normothermic machine perfusion of human kidneys. Science Translational Medicine, 2017, 9, .	5.8	104
61	Anti-tumor Activity of miniPEG-Î³-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy. Molecular Therapy - Nucleic Acids, 2017, 9, 111-119.	2.3	61
62	Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities. Yale Journal of Biology and Medicine, 2017, 90, 583-598.	0.2	65
63	Pigment epitheliumâ€derived factor restoration increases bone mass and improves bone plasticity in a model of osteogenesis imperfecta type VI via Wnt3a blockade. FASEB Journal, 2016, 30, 2837-2848.	0.2	28
64	Distribution of polymer nanoparticles by convection-enhanced delivery to brain tumors. Journal of Controlled Release, 2016, 232, 103-112.	4.8	65
65	Multifunctional Poly(amine-co-ester-co-orthoester) for Efficient and Safe Gene Delivery. ACS Biomaterials Science and Engineering, 2016, 2, 2080-2089.	2.6	17
66	Improved i.p. drug delivery with bioadhesive nanoparticles. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11453-11458.	3.3	62
67	PEGylated squalenoyl-gemcitabine nanoparticles for the treatment ofÂglioblastoma. Biomaterials, 2016, 105, 136-144.	5.7	55
68	In vivo correction of anaemia in Î²-thalassemic mice by Î³PNA-mediated gene editing with nanoparticle delivery. Nature Communications, 2016, 7, 13304.	5.8	143
69	Nanotechnology for delivery of peptide nucleic acids (PNAs). Journal of Controlled Release, 2016, 240, 302-311.	4.8	55
70	Nanoparticle delivery of miR-223 to attenuate macrophage fusion. Biomaterials, 2016, 89, 127-135.	5.7	25
71	miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 927-939.	0.4	128
72	Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomaterialia, 2016, 30, 49-61.	4.1	81

#	Article	IF	Citations
73	Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight, 2016, 1, .	2.3	58
74	Clostridium perfringens enterotoxin <scp>C</scp>â€terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapyâ€resistant ovarian cancer. International Journal of Cancer, 2015, 137, 2618-2629.	2.3	27
75	Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. ACS Biomaterials Science and Engineering, 2015, 1, 64-78.	2.6	151
76	A holistic approach to targeting disease with polymeric nanoparticles. Nature Reviews Drug Discovery, 2015, 14, 239-247.	21.5	373
77	Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium. Nature Communications, 2015, 6, 6952.	5.8	114
78	Efficient Gene Disruption in Cultured Primary Human Endothelial Cells by CRISPR/Cas9. Circulation Research, 2015, 117, 121-128.	2.0	64
79	A sunblock based on bioadhesive nanoparticles. Nature Materials, 2015, 14, 1278-1285.	13.3	167
80	Tissue-Engineered Microvasculature to Reperfuse Isolated Renal Glomeruli. Tissue Engineering - Part A, 2015, 21, 2673-2679.	1.6	1
81	Systemic delivery of bloodâ€“brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissue. Journal of Drug Targeting, 2015, 23, 736-749.	2.1	73
82	Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6597-605.	3.3	11
83	Nanomedicine gets personal. Science Translational Medicine, 2015, 7, 314fs47.	5.8	27
84	Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance. Journal of Neuro-Oncology, 2015, 121, 441-449.	1.4	44
85	Controlled protein delivery in the generation of microvascular networks. Drug Delivery and Translational Research, 2015, 5, 75-88.	3.0	8
86	MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature, 2015, 518, 107-110.	13.7	709
87	Modified Poly(lacticâ€coâ€glycolic Acid) Nanoparticles for Enhanced Cellular Uptake and Gene Editing in the Lung. Advanced Healthcare Materials, 2015, 4, 361-366.	3.9	37
88	Targeted Genome Modification via Triple Helix Formation. Methods in Molecular Biology, 2014, 1176, 89-106.	0.4	20
89	Controlled release for local delivery of drugs: barriers and models. Journal of Controlled Release, 2014, 190, 664-673.	4.8	163
90	Cell Interactions with Polymers. , 2014, , 385-406.		23

#	Article	IF	Citations
91	Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer. Molecular Cancer Therapeutics, 2014, 13, 71-81.	1.9	63
92	The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials, 2014, 35, 6595-6602.	5.7	121
93	Sustained delivery of proangiogenic microRNAâ€132 by nanoparticle transfection improves endothelial cell transplantation. FASEB Journal, 2014, 28, 908-922.	0.2	72
94	Radiolabeling of Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles with Biotinylated F-18 Prosthetic Groups and Imaging of Their Delivery to the Brain with Positron Emission Tomography. Bioconjugate Chemistry, 2014, 25, 2157-2165.	1.8	45
95	Multi-layered nanoparticles for combination gene and drug delivery to tumors. Biomaterials, 2014, 35, 9343-9354.	5.7	55
96	Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E3062-71.	3.3	31
97	The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials, 2014, 35, 1089-1095.	5.7	64
98	The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation. Biomaterials, 2014, 35, 6698-6706.	5.7	48
99	An electrospun scaffold integrating nucleic acid delivery for treatment of full-thickness wounds. Biomaterials, 2013, 34, 3891-3901.	5.7	89
100	Regeneration of mammalian cochlear and vestibular hair cells through Hes1/Hes5 modulation with siRNA. Hearing Research, 2013, 304, 91-110.	0.9	34
101	Paracrine exchanges of molecular signals between alginate-encapsulated pericytes and freely suspended endothelial cells within a 3D protein gel. Biomaterials, 2013, 34, 8899-8908.	5.7	24
102	Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Therapy, 2013, 20, 658-669.	2.3	71
103	Pericytes modulate endothelial sprouting. Cardiovascular Research, 2013, 100, 492-500.	1.8	55
104	Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 1124-1134.	1.7	51
105	Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11751-11756.	3.3	222
106	Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics. Current Medicinal Chemistry, 2013, 20, 3582-3593.	1.2	48
107	A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.. Journal of Clinical Oncology, 2013, 31, e15543-e15543.	0.8	0
108	Novel Delivery Strategies for Glioblastoma. Cancer Journal (Sudbury, Mass), 2012, 18, 89-99.	1.0	109

#	Article	IF	Citations
109	Surface modified poly(Î² amino ester)-containing nanoparticles for plasmid DNA delivery. Journal of Controlled Release, 2012, 164, 41-48.	4.8	75
110	Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nature Materials, 2012, 11, 82-90.	13.3	360
111	Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative Splicing. Molecular Pharmaceutics, 2012, 9, 1481-1488.	2.3	84
112	Downsizing tumour therapeutics. Nature Nanotechnology, 2012, 7, 346-347.	15.6	20
113	Enhanced growth and hepatic differentiation of fetal liver epithelial cells through combinational and temporal adjustment of soluble factors. Biotechnology Journal, 2012, 7, 440-448.	1.8	5
114	Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1695-704.	3.3	439
115	Polymeric nanoparticles for drug delivery to the central nervous system. Advanced Drug Delivery Reviews, 2012, 64, 701-705.	6.6	427
116	Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials, 2012, 33, 583-591.	5.7	160
117	Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. Journal of Controlled Release, 2012, 162, 102-110.	4.8	99
118	Therapeutic siRNA: principles, challenges, and strategies. Yale Journal of Biology and Medicine, 2012, 85, 187-200.	0.2	199
119	Nanoparticles Deliver Triplex-forming PNAs for Site-specific Genomic Recombination in CD34+ Human Hematopoietic Progenitors. Molecular Therapy, 2011, 19, 172-180.	3.7	86
120	Polymer delivery systems for site-specific genome editing. Journal of Controlled Release, 2011, 155, 312-316.	4.8	15
121	Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. Journal of Controlled Release, 2011, 156, 109-115.	4.8	72
122	In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. Journal of Controlled Release, 2011, 156, 258-264.	4.8	117
123	Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Delivery and Translational Research, 2011, 1, 34-42.	3.0	98
124	Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles. Drug Delivery and Translational Research, 2011, 1, 383-394.	3.0	21
125	Enzymeâ€synthesized poly(amineâ€coâ€esters) as nonviral vectors for gene delivery. Journal of Biomedical Materials Research - Part A, 2011, 96A, 456-465.	2.1	41
126	Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials, 2011, 32, 6194-6203.	5.7	106

#	Article	IF	Citations
127	Biodegradation, biocompatibility, and drug delivery in poly(ï‰-pentadecalactone-co-p-dioxanone) copolyesters. Biomaterials, 2011, 32, 6646-6654.	5.7	49
128	Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cellâ€“based antitumor immunotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 1-10.	1.7	86
129	Tissueâ€engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB Journal, 2011, 25, 2731-2739.	0.2	136
130	Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization. Biomaterials, 2010, 31, 3054-3062.	5.7	85
131	Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 334-343.	1.7	23
132	Are We Studying What Matters? Health Priorities and NIH-Funded Biomedical Engineering Research. Annals of Biomedical Engineering, 2010, 38, 2237-2251.	1.3	4
133	Parameter estimation methodology in a model of hydrophobic drug release from a polymer coating. Journal of Controlled Release, 2010, 142, 474-482.	4.8	30
134	The behavioral and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats. Brain Research, 2010, 1321, 40-50.	1.1	43
135	Poly(lactide-co-glycolide) nanoparticle assembly for highly efficient delivery of potent therapeutic agents from medical devices. Biomaterials, 2010, 31, 3631-3642.	5.7	36
136	Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4669-4674.	3.3	495
137	Vaccine Delivery by Polymeric Vehicles in the Mouse Reproductive Tract Induces Sustained Local and Systemic Immunity. Molecular Pharmaceutics, 2010, 7, 1585-1595.	2.3	21
138	Partial Correction of Cystic Fibrosis Defects with PLGA Nanoparticles Encapsulating Curcumin. Molecular Pharmaceutics, 2010, 7, 86-93.	2.3	123
139	Biodegradable Meshes Printed with Extracellular Matrix Proteins Support Micropatterned Hepatocyte Cultures. Tissue Engineering - Part A, 2009, 15, 1169-1179.	1.6	26
140	Human Aortic Smooth Muscle Cells Promote Arteriole Formation by Coengrafted Endothelial Cells. Tissue Engineering - Part A, 2009, 15, 165-173.	1.6	48
141	Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. Journal of Controlled Release, 2009, 134, 26-34.	4.8	167
142	Shining light on a new class of hydrogels. Nature Biotechnology, 2009, 27, 543-544.	9.4	26
143	Stealth particles give mucus the slip. Nature Materials, 2009, 8, 11-13.	13.3	72
144	Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nature Materials, 2009, 8, 526-533.	13.3	415

#	Article	IF	Citations
145	PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2009, 5, 410-418.	1.7	303
146	Nanotechnology for Delivery of Drugs to the Brain for Epilepsy. Neurotherapeutics, 2009, 6, 323-336.	2.1	117
147	Simultaneous release of multiple molecules from poly(lactide-co-glycolide) nanoparticles assembled onto medical devices. Biomaterials, 2009, 30, 4889-4897.	5.7	20
148	The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials, 2009, 30, 2790-2798.	5.7	363
149	Poly(Ï‰-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials, 2009, 30, 5707-5719.	5.7	100
150	Mathematical modeling of molecular diffusion through mucus. Advanced Drug Delivery Reviews, 2009, 61, 101-114.	6.6	104
151	Engineered molecular delivery for control and enhancement of transplanted endothelial cell fate in tissue engineering. , 2009, , .		0
152	Controlled Surface Modification with Poly(ethylene)glycol Enhances Diffusion of PLGA Nanoparticles in Human Cervical Mucus. Molecular Pharmaceutics, 2009, 6, 173-181.	2.3	231
153	Cellular Fate of a Modular DNA Delivery System Mediated by Silica Nanoparticles. Biotechnology Progress, 2008, 21, 532-537.	1.3	99
154	High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. Journal of Controlled Release, 2008, 129, 66-72.	4.8	101
155	Bioengineering Approaches to Controlled Protein Delivery. Pediatric Research, 2008, 63, 513-519.	1.1	51
156	Effect of Extracellular Matrix Elements on the Transport of Paclitaxel through an Arterial Wall Tissue Mimic. Biomacromolecules, 2008, 9, 2792-2798.	2.6	25
157	Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation. FASEB Journal, 2008, 22, 2949-2956.	0.2	60
158	Replacement of Bone Marrow by Bone in Rat Femurs: The Bone Bioreactor. Tissue Engineering - Part A, 2008, 14, 237-246.	1.6	17
159	Centrifugal Seeding Increases Seeding Efficiency and Cellular Distribution of Bone Marrow Stromal Cells in Porous Biodegradable Scaffolds. Tissue Engineering, 2007, 13, 2743-2749.	4.9	79
160	Development of PTH Eluting Microspheres for the Treatment of Hypoparathyroidism. Journal of Surgical Research, 2007, 143, 195-199.	0.8	4
161	Efficacy of camptothecin and polymer-conjugated camptothecin in tumor spheroids and solid tumors. Journal of Biomaterials Science, Polymer Edition, 2007, 18, 1283-1299.	1.9	10
162	Conjugation to Increase Treatment Volume during Local Therapy: A Case Study with PEGylated Camptothecin. Bioconjugate Chemistry, 2007, 18, 2115-2121.	1.8	12

#	Article	IF	Citations
163	A nanoscopic multivalent antigen-presenting carrier for sensitive detection and drug delivery to T Cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 75-85.	1.7	25
164	Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Research, 2007, 1180, 121-132.	1.1	90
165	Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS Journal, 2007, 9, E171-E180.	2.2	89
166	Fibronectin terminated multilayer films: Protein adsorption and cell attachment studies. Biomaterials, 2007, 28, 851-860.	5.7	203
167	A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Experimental Eye Research, 2006, 83, 824-833.	1.2	90
168	Development of a model system for preliminary evaluation of tissue-engineered vascular conduits. Journal of Pediatric Surgery, 2006, 41, 787-791.	0.8	21
169	Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology, 2006, 117, 78-88.	2.0	373
170	In vitro evaluation of biodegradable microspheres with surface-bound ligands. Journal of Controlled Release, 2006, 110, 574-580.	4.8	38
171	Impact of Cell Type and Density on Nerve Growth Factor Distribution and Bioactivity in 3-Dimensional Collagen Gel Cultures. Tissue Engineering, 2006, 12, 1915-1927.	4.9	30
172	New methods for direct delivery of chemotherapy for treating brain tumors. Yale Journal of Biology and Medicine, 2006, 79, 141-52.	0.2	94
173	The influence of microchannels on neurite growth and architecture. Biomaterials, 2005, 26, 771-778.	5.7	211
174	Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials, 2005, 26, 5727-5736.	5.7	174
175	Diffusion measurements for drug design. Nature Materials, 2005, 4, 714-714.	13.3	1
176	Improved cell adhesion and proliferation on synthetic phosphonic acid-containing hydrogels. Biomaterials, 2005, 26, 3663-3671.	5.7	119
177	Development of a parathyroid hormone-controlled release system as a potential surgical treatment for hypoparathyroidism. Journal of Pediatric Surgery, 2005, 40, 81-85.	0.8	8
178	Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion. Nature Materials, 2004, 3, 489-494.	13.3	30
179	Surface-mediated gene transfer from nanocomposites of controlled texture. Nature Materials, 2004, 3, 569-574.	13.3	188
180	A self-assembled, modular DNA delivery system mediated by silica nanoparticles. Journal of Controlled Release, 2004, 95, 333-341.	4.8	166

#	Article	IF	Citations
181	Improving the expansion and neuronal differentiation of mesenchymal stem cells through culture surface modification. Biomaterials, 2004, 25, 1331-1337.	5.7	179
182	Biomaterials with hierarchically defined micro- and nanoscale structure. Biomaterials, 2004, 25, 3593-3601.	5.7	200
183	The effect of synthetic polymers on the migration of monocytes through human cervical mucus. Biomaterials, 2004, 25, 4563-4571.	5.7	10
184	Biodegradable Microspheres with Enhanced Capacity for Covalently Bound Surface Ligands. Macromolecules, 2004, 37, 9779-9784.	2.2	68
185	In Vitro Cytotoxicity and in Vivo Distribution after Direct Delivery of PEGâ^'Camptothecin Conjugates to the Rat Brain. Bioconjugate Chemistry, 2004, 15, 1364-1375.	1.8	62
186	Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. Journal of Controlled Release, 2003, 86, 339-348.	4.8	48
187	Organosilicate-polymer drug delivery systems: controlled release and enhanced mechanical properties. Journal of Controlled Release, 2003, 90, 163-169.	4.8	133
188	Biomimetic design in microparticulate vaccines. Biomaterials, 2003, 24, 4435-4443.	5.7	31
189	Diffusion of Nerve Growth Factor in Rat Striatum as Determined by Multiphoton Microscopy. Biophysical Journal, 2003, 85, 581-588.	0.2	68
190	Malolactonate polymers and copolymers for biomedical applications. Macromolecular Symposia, 2003, 197, 303-314.	0.4	4
191	Surface patterning and biological evaluation of semi-interpenetrated poly(HEMA)/poly(alkylÎ²-malolactonate)s. Macromolecular Symposia, 2003, 197, 369-380.	0.4	8
192	Poly(ethylene glycol)-Conjugated PAMAM Dendrimer for Biocompatible, High-Efficiency DNA Delivery. Macromolecules, 2002, 35, 3456-3462.	2.2	388
193	Pharmacokinetics of the Carmustine Implant. Clinical Pharmacokinetics, 2002, 41, 403-419.	1.6	236
194	Influence of structural parameters on the ring-opening polymerization of new alkyl malolactonate monomers and on the biocompatibility of polymers therefrom. Macromolecular Chemistry and Physics, 2002, 203, 1684-1693.	1.1	12
195	Building drug delivery into tissue engineering design. Nature Reviews Drug Discovery, 2002, 1, 177-186.	21.5	290
196	Micron-Scale Positioning of Features Influences the Rate of Polymorphonuclear Leukocyte Migration. Biophysical Journal, 2001, 81, 2569-2579.	0.2	51
197	Transplantation of brain cells assembled around a programmable synthetic microenvironment. Nature Biotechnology, 2001, 19, 934-939.	9.4	131
198	Aggregation Enhances Catecholamine Secretion in Cultured Cells. Tissue Engineering, 2001, 7, 179-190.	4.9	18

#	Article	IF	Citations
199	Fibroblast aggregation by suspension with conjugates of poly(ethylene glycol) and RGD. , 2000, 50, 349-356.		20
200	Long-term vaginal antibody delivery: Delivery systems and biodistribution. , 2000, 67, 253-264.		26
201	Controlling human polymorphonuclear leukocytes motility using microfabrication technology. Journal of Biomedical Materials Research Part B, 2000, 51, 694-702.	3.0	28
202	Synthetic DNA delivery systems. Nature Biotechnology, 2000, 18, 33-37.	9.4	1,494
203	Enhancement of transfection by physical concentration of DNA at the cell surface. Nature Biotechnology, 2000, 18, 893-895.	9.4	532
204	Delivering tissue regeneration. Nature Biotechnology, 1999, 17, 534-535.	9.4	38
205	Controlled DNA delivery systems. Pharmaceutical Research, 1999, 16, 1300-1308.	1.7	144
206	Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharmaceutical Research, 1999, 16, 232-240.	1.7	94
207	Influence of synthetic polymers on neutrophil migration in three-dimensional collagen gels. Journal of Biomedical Materials Research Part B, 1999, 46, 465-474.	3.0	35
208	Cultures of cells from fetal rat brain: Methods to control composition, morphology, and biochemical activity. , 1999, 62, 461-467.		15
209	Synthesis and Biological Activity of Polyethylene Glycolâ^'Mouse Nerve Growth Factor Conjugate. Bioconjugate Chemistry, 1999, 10, 932-937.	1.8	24
210	Antibodies to CD18 influence neutrophil migration through extracellular matrix. Journal of Leukocyte Biology, 1999, 65, 356-363.	1.5	17
211	Localized delivery of proteins in the brain: can transport be customized?. , 1998, 15, 377-385.		46
212	Topical antibody delivery systems produce sustained levels in mucosal tissue and blood. Nature Biotechnology, 1998, 16, 163-167.	9.4	25
213	Materials for protein delivery in tissue engineering. Advanced Drug Delivery Reviews, 1998, 33, 71-86.	6.6	216
214	Synthesis and characterization of polymer-(multi)-peptide conjugates for control of specific cell aggregation. Journal of Biomaterials Science, Polymer Edition, 1998, 9, 207-226.	1.9	31
215	Stabilization of nerve growth factor in controlled release polymers and in tissue. Journal of Biomaterials Science, Polymer Edition, 1997, 8, 103-117.	1.9	56
216	Polymeric controlled delivery for immunization. Trends in Biotechnology, 1997, 15, 364-369.	4.9	25

#	Article	IF	Citations
217	PC12 CELL AGGREGATION AND NEURITE GROWTH IN GELS OF COLLAGEN, LAMININ AND FIBRONECTIN. International Journal of Developmental Neuroscience, 1996, 14, 351-364.	0.7	58
218	Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharmaceutical Research, 1996, 13, 671-682.	1.7	190
219	Transport and elimination of recombinant human NGF during long-term delivery to the brain. Brain Research, 1996, 727, 169-181.	1.1	90
220	Oral immunization with an antiâ€“idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nature Medicine, 1996, 2, 1116-1121.	15.2	71
221	Controlled Release of Proteins to Tissue Transplants for the Treatment of Neurodegenerative Disorders. Journal of Pharmaceutical Sciences, 1996, 85, 1276-1281.	1.6	56
222	Residence half-life of IgG administered topically to the mouse vagina. Biology of Reproduction, 1996, 54, 264-269.	1.2	30
223	Growth-Factor Delivery in Tissue Engineering. MRS Bulletin, 1996, 21, 62-65.	1.7	29
224	Nerve Growth Factor Delivery and Cell Aggregation Enhance Choline Acetyltransferase Activity after Neural Transplantation. Tissue Engineering, 1996, 2, 183-196.	4.9	14
225	Fibroblast aggregation by suspension with conjugates of poly(ethylene glycol) and RGD. Biotechnology and Bioengineering, 1996, 50, 349-356.	1.7	23
226	Distribution of drugs following controlled delivery to the brain interstitium. Journal of Neuro-Oncology, 1995, 26, 91-102.	1.4	54
227	Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Research, 1995, 680, 196-206.	1.1	194
228	Controlled release of macromolecules from a degradable polyanhydride matrix. Journal of Biomaterials Science, Polymer Edition, 1995, 6, 297-311.	1.9	19
229	Cell aggregation and neurite growth in gels of extracellular matrix molecules. Biotechnology and Bioengineering, 1994, 43, 555-562.	1.7	61
230	Cell-binding Peptides Conjugated to Poly(ethylene glycol) Promote Neural Cell Aggregation. Nature Biotechnology, 1994, 12, 797-801.	9.4	48
231	Controlled antibody release from a matrix of poly(ethylene-co-vinyl acetate) fractionated with a supercritical fluid. Journal of Applied Polymer Science, 1993, 48, 1493-1500.	1.3	35
232	Growth versus function in the three-dimensional culture of single and aggregated hepatocytes within collagen gels. Biotechnology Progress, 1993, 9, 600-607.	1.3	53
233	Controlled Vaginal Delivery of Antibodies in the Mouse1. Biology of Reproduction, 1992, 47, 133-140.	1.2	53
234	Controlled Antibody Delivery Systems. Nature Biotechnology, 1992, 10, 1446-1449.	9.4	17

#	Article	IF	Citations
235	Dextran retention in the rat brain following release from a polymer implant. Biotechnology Progress, 1992, 8, 527-532.	1.3	24
236	Fibroblast and hepatocyte behavior on synthetic polymer surfaces. Journal of Biomedical Materials Research Part B, 1991, 25, 741-759.	3.0	42
237	Controlled release of nerve growth factor from a polymeric implant. Brain Research, 1990, 515, 309-311.	1.1	98
238	Controlled release of dopamine from a polymeric brain implant: In vivo characterization. Annals of Neurology, 1989, 25, 351-356.	2.8	99
239	Quantitative image analysis for developing microstructural descriptions of heterogeneous materials. Chemical Engineering Science, 1987, 42, 1989-2004.	1.9	28
240	Biomolecular Engineering I: Biotechnology. , 0, , 472-506.		0